Alex Ganetsky1, Todd A Miano2, Mitchell E Hughes3, Robert H Vonderheide4, David L Porter5, Ran Reshef6. 1. Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 2. Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA. 4. Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 5. Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 6. Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA ran.reshef@uphs.upenn.edu.
Abstract
OBJECTIVES: Emerging data suggest that the combination of tacrolimus and the CCR5 antagonist maraviroc, both cytochrome P450-3A4 substrates, may be effective in preventing graft-versus-host disease in patients undergoing allogeneic HSCT. This study evaluated whether a pharmacokinetic interaction exists between these agents. METHODS: The study included 36 allogeneic HSCT recipients who received maraviroc + tacrolimus and 43 recipients of tacrolimus alone. We used a difference-in-differences analysis to examine the change in the concentration/dose ratios of tacrolimus after the discontinuation of maraviroc. In addition, we analysed the concentrations and dose requirements of tacrolimus in the two groups. RESULTS: There was no significant difference in tacrolimus concentration/dose ratios in patients receiving maraviroc + tacrolimus compared with tacrolimus alone. Upon discontinuation of maraviroc, the change in concentration/dose ratio was small and not significant relative to the control group, and the effect estimate was further attenuated after adjustment for confounders [-0.35 (ng/mL)/(mg/day); P = 0.46]. In addition, the change in mean tacrolimus dose after discontinuation of maraviroc was similar between the groups (0.12 mg/day; P = 0.56), as was the change in mean tacrolimus concentration (0.02 ng/mL; P = 0.97). CONCLUSIONS: Our findings do not support a significant inhibitory effect of maraviroc on the metabolism of tacrolimus. These data demonstrate that this drug combination is safe and imply that the protective effect of maraviroc against graft-versus-host disease was not mediated through an increase in tacrolimus concentrations. These findings are important for the design of clinical trials that evaluate maraviroc in combination with cytochrome P450-3A4 substrates.
OBJECTIVES: Emerging data suggest that the combination of tacrolimus and the CCR5 antagonist maraviroc, both cytochrome P450-3A4 substrates, may be effective in preventing graft-versus-host disease in patients undergoing allogeneic HSCT. This study evaluated whether a pharmacokinetic interaction exists between these agents. METHODS: The study included 36 allogeneic HSCT recipients who received maraviroc + tacrolimus and 43 recipients of tacrolimus alone. We used a difference-in-differences analysis to examine the change in the concentration/dose ratios of tacrolimus after the discontinuation of maraviroc. In addition, we analysed the concentrations and dose requirements of tacrolimus in the two groups. RESULTS: There was no significant difference in tacrolimus concentration/dose ratios in patients receiving maraviroc + tacrolimus compared with tacrolimus alone. Upon discontinuation of maraviroc, the change in concentration/dose ratio was small and not significant relative to the control group, and the effect estimate was further attenuated after adjustment for confounders [-0.35 (ng/mL)/(mg/day); P = 0.46]. In addition, the change in mean tacrolimus dose after discontinuation of maraviroc was similar between the groups (0.12 mg/day; P = 0.56), as was the change in mean tacrolimus concentration (0.02 ng/mL; P = 0.97). CONCLUSIONS: Our findings do not support a significant inhibitory effect of maraviroc on the metabolism of tacrolimus. These data demonstrate that this drug combination is safe and imply that the protective effect of maraviroc against graft-versus-host disease was not mediated through an increase in tacrolimus concentrations. These findings are important for the design of clinical trials that evaluate maraviroc in combination with cytochrome P450-3A4 substrates.
Authors: Anthony D Harris; Douglas D Bradham; Mona Baumgarten; Ilene H Zuckerman; Jeffrey C Fink; Eli N Perencevich Journal: Clin Infect Dis Date: 2004-05-12 Impact factor: 9.079
Authors: Ngozi E Dufty; Gerry Gilleran; Daniel Hawkins; Laura J Else; Stephen Taylor Journal: J Antimicrob Chemother Date: 2012-12-18 Impact factor: 5.790
Authors: M Murai; H Yoneyama; A Harada; Z Yi; C Vestergaard; B Guo; K Suzuki; H Asakura; K Matsushima Journal: J Clin Invest Date: 1999-07 Impact factor: 14.808
Authors: Marco Velasco-Velázquez; Xuanmao Jiao; Marisol De La Fuente; Timothy G Pestell; Adam Ertel; Michael P Lisanti; Richard G Pestell Journal: Cancer Res Date: 2012-05-25 Impact factor: 12.701
Authors: Mitesh S Patel; Kevin G Volpp; Dylan S Small; Alexander S Hill; Orit Even-Shoshan; Lisa Rosenbaum; Richard N Ross; Lisa Bellini; Jingsan Zhu; Jeffrey H Silber Journal: JAMA Date: 2014-12-10 Impact factor: 56.272
Authors: Søren Rud Kristensen; Rachel Meacock; Alex J Turner; Ruth Boaden; Ruth McDonald; Martin Roland; Matthew Sutton Journal: N Engl J Med Date: 2014-08-07 Impact factor: 91.245
Authors: Todd A Miano; Judd D Flesch; Rui Feng; Caitlin M Forker; Melanie Brown; Michelle Oyster; Laurel Kalman; Melanie Rushefski; Edward Cantu; Mary Porteus; Wei Yang; A Russel Localio; Joshua M Diamond; Jason D Christie; Michael G S Shashaty Journal: Clin Pharmacol Ther Date: 2019-10-20 Impact factor: 6.875
Authors: Kathryn T Maples; Molly Maloy; Sean Devlin; Andrew Lin; Lauren DeRespiris; Meagan Griffin; Carmen Lau; Anthony J Proli; Genovefa A Papanicolaou; Susan K Seo; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Valkal Bhatt Journal: Bone Marrow Transplant Date: 2020-01-14 Impact factor: 5.483